Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b mechanism of action (MOA) study in adults with overweight/obesity with and without T2D to assess its impact on glucose homeostasis

Next Previous
Trial Profile

Phase 1b mechanism of action (MOA) study in adults with overweight/obesity with and without T2D to assess its impact on glucose homeostasis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 868 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions

Most Recent Events

  • 26 Sep 2023 According to a Carmot Therapeutics media release, data from this trial will be presented at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany.
  • 01 Jun 2023 New trial record
  • 25 May 2023 According to a Carmot Therapeutics media release, data from this trial will be presented at the 83rd American Diabetes Association Scientific Sessions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top